1 萧信生等译.神经递质与中枢神经系统疾病.南京:南京大学出版社，1988. 2 Hardy J, Adolfsso R, Alaftrzof I. Trartamitter deficits in Alzheimer's disease. Neurochem Int, 1985,7:545. 3 李静，吴馥梅.神经营养因子对认知功能障碍的治疗前景.中国生化药物杂志，1995,16(3):1.43. 4 陈执中，程务本.刺梨SOD制剂的药效学及其临床应用进展.临床药学.1993,2(3):42. 5 Cutler RG. Superoxide diarrrotase, longevity and ,specific metabolic rate. Gerontat,1989,29:113. 6 陈执中.章月华.生化新药研究动向中国药学杂志，1994,29(1):12 7 生物工程信息快报，1993,(7):9. 8 马大龙.细胞因子基因工程进展.中国生化药物杂志.1994,15(3):221. 9 Chatellirr G, Lacomblez L. Taecrine(tetrahydroaminoacr-ine:THA)and lecithin in senile dementia of the Alzheimer type: A multicentre trial. Br Med J, 1990,300:495. 10 Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randurnized controlled trial of high-dose tacroine in patients with Alzhiemer' s disease.J Am Med Assoc, 1994,271:985. 11 Liu JS, Zhu YL, Yu CM, et al .The structrue of huperzine A and B, two new alkaloids exhibiting marked anti-cholinesterase activity. Can J Chem, 1986,64:837. 12 Zhang SL. Therapeutic effects of huperzine A on the aged with memory impairment. New Drug Clin Remedies,1986, 5:260. 13 Xu Sisum, Gao Zhixo, Weng Zheng, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer' s disease. Acta Pharmacol Sin, 1995,16(5):391. 14 Jackson WJ, Buccafusco JJ, Terry AV, et al. Valnacrine maleate improves delayed matching performance by aged monkeys.Pschopharmacol Berl, 1995,119(4):391. 15 Antuono PG. Effectiveness and safety of valnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane study group. Arch Intern Med, 1995.155(16):1766. 16 涂佳生.酶抑制剂与新药开发.中国医药情报，1995,1(1):58. 17 金伟华.富山公司的阿耳茨海默氏病药在英国试验.国外药讯，1996,(2):18. 18 刘静.卫材公司的痴呆治疗药研究取得进展.国外药讯，1996.(2):21.